A

Arkansas Research Trials | North Little Rock

Research site
(Unclaimed)
Location
4261 Stockton Drive Suite 203, North Little Rock, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Remibrutinib
RBX2660
Upadacitinib
Lebrikizumab
Rocatinlimab
RPT193
Daxdilimab
Povorcitinib
Sofpironium Bromide
Dupilumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 17 total trials

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart
Recently updated

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab
Locations recently updated

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo
Locations recently updated

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatm...

Enrolling
Angioedema
Hives
Drug: Placebo
Drug: Povorcitinib

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Enrolling
Discoid Lupus Erythematosus
Drug: Daxdilimab
Drug: Placebo/Daxdilimab

Trial sponsors

Lilly logo
Amgen logo
AbbVie logo
Novartis logo
R
B
E
Incyte logo
RAPT Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems